Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials

Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials

Abstract Currently, pyridostigmine bromide is an indispensable anticholinesterase agent used worldwide to treat patients with Myasthenia Gravis (MG). However, pyridostigmine bromide was unsuccessful in its “pioneering trials” to treat a series of MG patients. There are important historical landmarks before pyridostigmine bromide becomes useful, safe and indispensable for MG therapy. After 70 years of these “pioneering trials”, this article reviews some historical aspects related to them, as well as other preliminary trials using pyridostigmine bromide as therapy for MG patients.

Saved in:
Bibliographic Details
Main Authors: LORENZONI,Paulo José, KAY,Cláudia Suemi Kamoi, DUCCI,Renata Dal-Prá, FUSTES,Otto Jesus Hernandez, WERNECK,Lineu Cesar, SCOLA,Rosana Herminia
Format: Digital revista
Language:English
Published: Academia Brasileira de Neurologia - ABNEURO 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000300179
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-282X2020000300179
record_format ojs
spelling oai:scielo:S0004-282X20200003001792020-04-22Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trialsLORENZONI,Paulo JoséKAY,Cláudia Suemi KamoiDUCCI,Renata Dal-PráFUSTES,Otto Jesus HernandezWERNECK,Lineu CesarSCOLA,Rosana Herminia myasthenia gravis pyridostigmine treatment history Abstract Currently, pyridostigmine bromide is an indispensable anticholinesterase agent used worldwide to treat patients with Myasthenia Gravis (MG). However, pyridostigmine bromide was unsuccessful in its “pioneering trials” to treat a series of MG patients. There are important historical landmarks before pyridostigmine bromide becomes useful, safe and indispensable for MG therapy. After 70 years of these “pioneering trials”, this article reviews some historical aspects related to them, as well as other preliminary trials using pyridostigmine bromide as therapy for MG patients.info:eu-repo/semantics/openAccessAcademia Brasileira de Neurologia - ABNEUROArquivos de Neuro-Psiquiatria v.78 n.3 20202020-03-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000300179en10.1590/0004-282x20190189
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author LORENZONI,Paulo José
KAY,Cláudia Suemi Kamoi
DUCCI,Renata Dal-Prá
FUSTES,Otto Jesus Hernandez
WERNECK,Lineu Cesar
SCOLA,Rosana Herminia
spellingShingle LORENZONI,Paulo José
KAY,Cláudia Suemi Kamoi
DUCCI,Renata Dal-Prá
FUSTES,Otto Jesus Hernandez
WERNECK,Lineu Cesar
SCOLA,Rosana Herminia
Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials
author_facet LORENZONI,Paulo José
KAY,Cláudia Suemi Kamoi
DUCCI,Renata Dal-Prá
FUSTES,Otto Jesus Hernandez
WERNECK,Lineu Cesar
SCOLA,Rosana Herminia
author_sort LORENZONI,Paulo José
title Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials
title_short Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials
title_full Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials
title_fullStr Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials
title_full_unstemmed Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials
title_sort celebrating the 70 years of pyridostigmine on therapy of myasthenia gravis: historical aspects of the preliminary trials
description Abstract Currently, pyridostigmine bromide is an indispensable anticholinesterase agent used worldwide to treat patients with Myasthenia Gravis (MG). However, pyridostigmine bromide was unsuccessful in its “pioneering trials” to treat a series of MG patients. There are important historical landmarks before pyridostigmine bromide becomes useful, safe and indispensable for MG therapy. After 70 years of these “pioneering trials”, this article reviews some historical aspects related to them, as well as other preliminary trials using pyridostigmine bromide as therapy for MG patients.
publisher Academia Brasileira de Neurologia - ABNEURO
publishDate 2020
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000300179
work_keys_str_mv AT lorenzonipaulojose celebratingthe70yearsofpyridostigmineontherapyofmyastheniagravishistoricalaspectsofthepreliminarytrials
AT kayclaudiasuemikamoi celebratingthe70yearsofpyridostigmineontherapyofmyastheniagravishistoricalaspectsofthepreliminarytrials
AT duccirenatadalpra celebratingthe70yearsofpyridostigmineontherapyofmyastheniagravishistoricalaspectsofthepreliminarytrials
AT fustesottojesushernandez celebratingthe70yearsofpyridostigmineontherapyofmyastheniagravishistoricalaspectsofthepreliminarytrials
AT wernecklineucesar celebratingthe70yearsofpyridostigmineontherapyofmyastheniagravishistoricalaspectsofthepreliminarytrials
AT scolarosanaherminia celebratingthe70yearsofpyridostigmineontherapyofmyastheniagravishistoricalaspectsofthepreliminarytrials
_version_ 1756374812876341248

Similar Items